Topic: Nexavar
Bayer and Onyx Pharmaceuticals say Nexavar does not meet study goal as a lung cancer treatmentBayer HealthCare and Onyx Pharmaceuticals Inc. said Monday their cancer treatment Nexavar failed to boost survival in a clinical study involving patients with a certain type of ...
The addition of Nexavar failed to prolong overall survival, the primary endpoint, although progression free survival was significantly extended. Nexavar or placebo will be administered as a monotherapy, plus best supportive care, and the primary endpoint is overall survival.. Results from the ...
Berlin, June 14, 2010 - Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar? (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed ...
WASHINGTON (Reuters) - Researchers said they helped advanced lung cancer patients fare better by matching their tumors to targeted drugs, in what they said is the first significant trial to show it is possible to choose the best drug for an individual ...
The number one cancer killer, lung cancer, may be more susceptible to treatment when doctors match up targeted drugs to tumors with key genetic traits, a new study finds.. One of the best -- and somewhat surprising -- results came when Nexavar ...
Bayer and biotech Onyx Pharmaceuticals announced a devastatingly disappointing result for their cancer pill Nexavar: They stopped a study of the drug in non-small cell lung cancer early because there was no chance it would reach its main goal of proving Nexavar ...
We have a couple of firms commenting on Onyx Pharma (NASDAQ: ONXX) after partner Bayer announced that Nexavar's Phase III trial in lung cancer was stopped early by the trial's data safety monitoring board because of futility. - Morgan Stanley maintains their ...
We have a couple of firms commenting on Onyx Pharma (NASDAQ: ONXX) after partner Bayer announced that Nexavar's Phase III trial in lung cancer was stopped early by the trial's data safety monitoring board because of futility. - Morgan Stanley maintains their ...
Bayer AG and Onyx Pharmaceuticals Inc said they have halted a phase III trial in which the two companies were testing their Nexavar kidney cancer drug on patients suffering from non-small cell lung cancer (NSCLC).. A panel of independent experts monitoring the ...
From Around the Web
Video Gallery
-
Cancer: Sorafenib (Nexavar) English
Mechanism of action for Sorafenib (Nexavar). Mécanisme d'action du ...2010-06-14 -
Liver CA: Benefit & Side Effects of ...
In November 2010, Mutu, 48 years old started having coughs ...2011-02-13 -
Pharma Pricing Analysis - Sutent vs. Nexavar ...
This pharma pricing video compares Sutent and Nexavar sales, quarterly ...2011-03-24
